Articles by SureFit

On October 31, 2025, CMS released its “CY 2026 Medicare Physician Fee Schedule Final Rule.”1 This Rule finalized a new payment model for skin substitute products applied to Medicare Part B beneficiaries during a covered application procedure in a non-facility setting and in the hospital outpatient department setting. 

Several ICD-10-CM code changes took effect on October 1, 2025,1 that will affect providers.

Several ICD-10-CM code changes took effect on October 1, 2025,1 that will affect providers.

Technology and AI are everywhere, promising to make your life easier by automating repetitive tasks. However, for many medical practices, the sheer number of tools and options can lead to decision paralysis. Where should you even begin? 

Many procedures have either a 10- or 90-day postoperative global period. Generally, any care provided within that period is included in the payment for the procedure. However, there are some exceptions. If a patient in a postoperative global period experiences a complication of the procedure for which they are in the global period and an evaluation and management (E&M) of that complication is performed, there is no modifier that allows for submission of that E&M. The only E&M modifier that can be used during a postoperative global period is the 24 Modifier which is only appropriate when an E&M service is performed for a problem unrelated to the procedure for which the patient is in the postoperative global period.

All seven Part B Medicare Administrative Contractors have finalized new, identical coverage policies that will govern the application of skin substitutes/cellular and tissue-based products applied to diabetic foot ulcers and venous leg ulcers for Medicare Part B beneficiaries. These policies only rigidly apply to diabetic foot ulcers and venous leg ulcers. These policies take effect January 1, 2026.